Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Aurinia Pharmaceuticals Inc

Healthcare US AUPH

17.53USD
1.07(6.50%)

Last update at 2026-06-22T20:21:00Z

Day Range

17.1618.40
LowHigh

52 Week Range

7.2916.54
LowHigh

Fundamentals

  • Previous Close 16.46
  • Market Cap2103.60M
  • Volume3388560
  • P/E Ratio7.64
  • Dividend Yield-%
  • EBITDA135.71M
  • Revenue TTM283.06M
  • Revenue Per Share TTM2.11
  • Gross Profit TTM 217.88M
  • Diluted EPS TTM2.07

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 114.16M 7.45M -77.46900M -106.35200M -180.20600M
Minority interest - - - - -
Net income 287.20M 5.75M -78.02000M -108.18000M -180.96600M
Selling general administrative 101.79M 157.93M 195.04M 196.37M 171.44M
Selling and marketing expenses - 14.09M - - -
Gross profit 250.39M 206.88M 161.37M 128.37M 44.51M
Reconciled depreciation 19.45M 19.45M 6.92M 2.71M 2.76M
Ebit 118.49M 12.28M -74.69400M -114.17600M -180.73500M
Ebitda 127.76M 31.73M -63.04700M -111.47000M -178.63700M
Depreciation and amortization 9.27M 19.45M 11.65M 2.71M 2.10M
Non operating income net other - - - - 0.53M
Operating income 104.91M -4.68700M -91.69100M -111.47000M -180.73500M
Other operating expenses 178.14M 239.82M 267.20M 245.50M 226.34M
Interest expense 4.33M 4.83M 2.77M 5.12M 0.53M
Tax provision -173.04500M 1.70M 0.95M 1.83M 0.76M
Interest income 13.57M 16.97M 15.34M 5.12M 0.53M
Net interest income 9.24M 12.13M 13.87M 5.12M 0.53M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -173.04500M 1.70M 0.55M 1.83M 0.76M
Total revenue 283.06M 235.13M 175.51M 134.03M 45.60M
Total operating expenses 145.48M 211.57M 253.06M 239.84M 225.25M
Cost of revenue 32.66M 28.25M 14.15M 5.66M 1.09M
Total other income expense net 9.24M 12.13M 14.22M 5.12M 0.53M
Discontinued operations - - - - -
Net income from continuing ops 287.20M 5.75M -77.19100M -108.18000M -180.96600M
Net income applicable to common shares - - - -108.18000M -180.96600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 751.59M 550.64M 548.06M 470.86M 543.37M
Intangible assets 3.76M 4.36M 4.98M 6.42M 8.40M
Earning assets - - - - -
Other current assets 6.83M 12.35M 10.52M 1.33M 0.80M
Total liab 170.26M 173.17M 170.11M 65.42M 64.28M
Total stockholder equity 581.33M 377.48M 377.95M 405.44M 479.09M
Deferred long term liab - - - - -
Other current liab 69.10M 66.50M 52.45M 38.94M 4.64M
Common stock 1120.04M 1187.70M 1200.22M 1185.31M 1177.05M
Capital stock 1120.04M 1187.70M 1200.22M 1185.31M 1177.05M
Retained earnings -649.36800M -936.57000M -942.32200M -864.30200M -756.12200M
Other liab - - - 12.17M 15.95M
Good will - - - - -
Other assets - - - 13.34M 11.84M
Cash 80.21M 83.43M 48.88M 94.17M 231.90M
Cash and equivalents - - - - -
Total current liabilities 93.72M 97.76M 77.19M 46.11M 40.65M
Current deferred revenue 3.72M 11.00M 4.81M 3.15M 31.07M
Net debt -5.40100M -4.06400M 48.73M -86.08400M -223.16100M
Short term debt 17.59M 15.07M 15.60M 0.94M 1.06M
Short long term debt - - - - -
Short long term debt total 74.81M 79.37M 97.61M 8.09M 8.74M
Other stockholder equity 111.26M 127.00M 120.79M 85.49M 59.01M
Property plant equipment - - - 8.56M 9.80M
Total current assets 491.97M 446.60M 424.80M 442.54M 513.32M
Long term investments - 0.00000M 0.20M - 0.00000M
Net tangible assets - - - 399.01M 470.69M
Short term investments 317.78M 275.04M 301.61M 295.22M 234.18M
Net receivables 41.45M 36.54M 24.09M 13.48M 15.41M
Long term debt - - - - -
Inventory 45.69M 39.23M 39.70M 24.75M 19.33M
Accounts payable 3.31M 5.19M 4.33M 3.09M 3.88M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.59900M -0.64700M -0.73000M -1.06100M -0.85200M
Additional paid in capital - - - - -
Common stock total equity - - - - 1177.05M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -756.12200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.09M 0.82M 1.52M 13.34M 11.84M
Deferred long term asset charges - - - - -
Non current assets total 259.62M 104.05M 123.26M 28.32M 30.04M
Capital lease obligations 74.81M 79.37M 97.61M 8.09M 8.74M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -32.51600M 39.26M -3.46700M -60.63200M -84.53100M
Change to liabilities - - - 3.75M 4.08M
Total cashflows from investing activities -32.76800M 39.26M -6.70600M -60.63200M -103.87000M
Net borrowings -13.13600M -11.98900M -10.02500M - -
Total cash from financing activities -106.11000M -49.09200M -5.13000M 2.43M 221.11M
Change to operating activities - - - -3.41900M -4.65000M
Net income 287.20M 5.75M -78.02000M -108.18000M -180.96600M
Change in cash -3.22000M 34.56M -45.29700M -137.72800M -40.45000M
Begin period cash flow 83.43M 48.88M 94.17M 231.90M 272.35M
End period cash flow 80.21M 83.43M 48.88M 94.17M 231.90M
Total cash from operating activities 135.66M 44.39M -33.46100M -79.52900M -157.69200M
Issuance of capital stock - - 0.00000M 0.00000M 196.74M
Depreciation 9.27M 19.45M 11.65M 2.71M 2.76M
Other cashflows from investing activities - -0.04300M -11.86400M -0.66300M -11.83800M
Dividends paid - - - - -
Change to inventory -6.46200M 0.48M -15.86900M -9.07200M -5.64400M
Change to account receivables -4.91000M -12.45500M -10.60600M 1.93M -15.41500M
Sale purchase of stock -98.15600M -40.23900M 0.00000M - 221.11M
Other cashflows from financing activities -9.76400M 3.14M 4.89M -60.63200M 24.37M
Change to netincome - - - 32.76M 42.15M
Capital expenditures 0.25M 0.28M 0.72M 0.29M 1.50M
Change receivables - - - - -15.41500M
Cash flows other operating - - - - 5.35M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -40.45000M
Change in working capital -8.78300M 5.45M -5.60800M -6.81700M -21.63300M
Stock based compensation 14.68M 31.60M 45.31M 32.30M 31.24M
Other non cash items 9.48M -17.85300M -6.79100M 0.46M 10.90M
Free cash flow 135.41M 44.11M -34.17900M -79.82100M -159.19300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AUPH
Aurinia Pharmaceuticals Inc		 1.07 6.50% 17.53 7.64 23.04 7.43 3.65 6.36 13.04
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

#140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6

Key Executives

Name Title Year Born
Mr. Peter S. Greenleaf M.B.A. Pres, CEO & Director 1970
Mr. Joseph M. Miller CPA Chief Financial Officer 1974
Mr. Matthew Maxwell Donley M.B.A. Exec. VP of Operations & Strategy 1969
Mr. Stephen P. Robertson Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer 1982
Ms. DeDe Sheel VP of Investor Relation NA
Mr. Chris Hays VP of Marketing NA
Mr. Fran Lynch VP of Sales NA
Mr. Michael R. Martin Chief Bus. Officer 1972
Ms. Sue Evans Head of Regulatory Affairs NA
Mr. Scott Habig Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.